

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT7987781

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Execution Date
NEURELIS, INC.	06/01/2023
AEGIS THERAPEUTICS, LLC	06/01/2023

RECEIVING PARTY DATA

Name:	ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP
Street Address:	601 LEXINGTON AVENUE, 54TH FLOOR
Internal Address:	C/O ORBIMED ADVISORS LLC
City:	NEW YORK
State/Country:	NEW YORK
Postal Code:	10022

PROPERTY NUMBERS Total: 12

Property Type	Number
Application Number:	18054273
Patent Number:	11458091
Application Number:	17881191
Application Number:	63384303
Application Number:	63384305
Application Number:	63384309
Application Number:	63384311
Application Number:	18062062
Application Number:	18125940
Application Number:	17837198
Application Number:	63350936
Application Number:	18149366

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: akwon@cov.com

Correspondent Name: COVINGTON & BURLING LLP

Address Line 1: ONE CITY CENTER, 850 TENTH ST NW
Address Line 2: ATTN: PATENT DOCKET
Address Line 4: WASHINGTON, D.C. 20001

ATTORNEY DOCKET NUMBER:	034550.00075
NAME OF SUBMITTER:	ASHLEY M. KWON
SIGNATURE:	/Ashley M. Kwon/
DATE SIGNED:	06/04/2023

Total Attachments: 5

source=Neurelis - Patent Security Agreement Supplement Execution Version#page1.tif
source=Neurelis - Patent Security Agreement Supplement Execution Version#page2.tif
source=Neurelis - Patent Security Agreement Supplement Execution Version#page3.tif
source=Neurelis - Patent Security Agreement Supplement Execution Version#page4.tif
source=Neurelis - Patent Security Agreement Supplement Execution Version#page5.tif

PATENT SECURITY AGREEMENT SUPPLEMENT

This PATENT SECURITY AGREEMENT SUPPLEMENT, dated as of June 1, 2023 (this "Agreement"), is made by Neurelis, Inc., a Delaware corporation (the "Borrower"), and Aegis Therapeutics, LLC, a California limited liability company (together with the Borrower, each a "Grantor" and collectively, the "Grantors"), in favor of ORBIMED ROYALTY & CREDIT OPPORTUNITIES III, LP, a Delaware limited partnership (together with its Affiliates, successors, transferees and assignees, the "Lender").

W I T N E S S E T H :

WHEREAS, pursuant to the Credit Agreement, dated as of August 5, 2021 (as amended, supplemented or otherwise modified from time to time, the "Credit Agreement"), by and between the Borrower and the Lender, the Lender has extended Commitments to make Loans to the Borrower;

WHEREAS, in connection with the Credit Agreement, the Grantors and their Affiliates have executed and delivered a Pledge and Security Agreement in favor of the Lender, dated as of August 5, 2021 (as amended, supplemented or otherwise modified from time to time, the "Security Agreement");

WHEREAS, pursuant to the Credit Agreement and pursuant to clause (f) of Section 4.5 of the Security Agreement, each Grantor is required to execute and deliver this Agreement and to grant to the Lender a continuing security interest in all of the Patent Collateral (as defined below) to secure all of the Obligations; and

WHEREAS, each Grantor has duly authorized the execution, delivery and performance of this Agreement;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, each Grantor agrees, for the benefit of the Lender, as follows:

SECTION 1. Definitions. Unless otherwise defined herein or the context otherwise requires, terms used in this Agreement, including its preamble and recitals, have the meanings provided (or incorporated by reference) in the Security Agreement.

SECTION 2. Grant of Security Interest. Each Grantor hereby grants to the Lender, for its benefit, a continuing security interest in all of such Grantor's right, title and interest in and to the Patent Collateral, including each patent and patent application referred to in Item A of Schedule I attached hereto and each patent license referred to in Item B of Schedule I attached hereto.

SECTION 3. Security Agreement. This Agreement has been executed and delivered by each Grantor for the purpose of registering the security interest of the Lender in the Patent Collateral with the United States Patent and Trademark Office. The security interest granted hereby has been granted in furtherance of, and not in limitation of, the security interest granted to the Lender for its benefit under the Security Agreement. The Security Agreement (and all rights and remedies of the Lender thereunder) shall remain in full force and effect in accordance with its terms.

SECTION 4. Release of Liens. Upon (a) the Disposition of Patent Collateral in accordance with the Credit Agreement or (b) the occurrence of the Termination Date, the security interests granted herein shall automatically terminate with respect to (i) such Patent Collateral (in the case of clause (a)) or (ii) all Patent Collateral (in the case of clause (b)). Upon any such Disposition or termination, the Lender will, at such Grantor's sole expense, deliver to such Grantor, without any representations, warranties or recourse of any kind whatsoever, all Patent Collateral held by the Lender hereunder, and execute and deliver to such Grantor such documents as such Grantor shall reasonably request to evidence such termination.

SECTION 5. Acknowledgment. Each Grantor does hereby further acknowledge and affirm that the rights and remedies of the Lender with respect to the security interest in the Patent Collateral granted hereby are more fully set forth in the Security Agreement, the terms and provisions of which (including the remedies provided for therein) are incorporated by reference herein as if fully set forth herein.

SECTION 6. Loan Document. This Agreement is a Loan Document executed pursuant to the Credit Agreement and shall (unless otherwise expressly indicated herein) be construed, administered and applied in accordance with the terms and provisions thereof, including Article X thereof.

SECTION 7. Governing Law. THIS AGREEMENT AND ANY CLAIMS, CONTROVERSY, DISPUTE OR CAUSE OF ACTION (WHETHER IN CONTRACT OR TORT OR OTHERWISE) BASED UPON, ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY DOCUMENT CONTEMPLATED HEREBY SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE INTERNAL LAWS OF THE STATE OF NEW YORK (INCLUDING FOR SUCH PURPOSE SECTIONS 5-1401 AND 5-1402 OF THE GENERAL OBLIGATIONS LAW OF THE STATE OF NEW YORK). This Agreement, along with the other Loan Documents, constitutes the entire understanding among the parties hereto with respect to the subject matter thereof and supersedes any prior agreements, written or oral, with respect thereto.

SECTION 8. Effectiveness. This Agreement shall become effective when a counterpart hereof executed by the Grantors, shall have been received by the Lender. Delivery of an executed counterpart of a signature page to this Agreement by email (e.g., "pdf" or "tiff") or telecopy shall be effective as delivery of a manually executed counterpart of this Agreement.

[Signature Page Follows.]

IN WITNESS WHEREOF, each Grantor hereto has caused this Agreement to be duly executed and delivered by its Authorized Officer as of the date first above written.

NEURELIS, INC.

By: *Brittany Bradrick*
Name: Brittany Bradrick
Title: Chief Financial Officer

AEGIS THERAPEUTICS, LLC
By: Neurelis, Inc., its sole member

By: *Brittany Bradrick*
Name: Brittany Bradrick
Title: Chief Financial Officer

[Signature Page to Patent Security Agreement Supplement]

PATENT
REEL: 063848 FRAME: 0213

SCHEDULE I
to Patent Security Agreement Supplement

Item A. Patents.

Case No.	Country Name	Application No.	Filing Date	Patent No.	Issue Date	Expiration Date / Expected Expiration Date (if pending)	Title	Owner Name	Status
148570-002271OB	UNITED STATES	18/054,273	11/10/2022			5/11/2025	ABSORPTION ENHANCERS FOR DRUG ADMINISTRATION	Aegis Therapeutics, LLC	PENDING
148570-003001	UNITED STATES	16/461,354	5/15/2019	11458091	10/4/2022	11/9/2037	COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPIOID OVERDOSE	Aegis Therapeutics, LLC Opiant Pharmaceuticals, Inc.	ISSUED
148570-003011	UNITED STATES	17/881,191	8/4/2022			11/9/2037	COMPOSITIONS AND METHODS FOR THE TREATMENT OF OPIOID OVERDOSE	AEGIS THERAPEUTICS, LLC OPIANT PHARMACEUTICALS, INC.	Pending
148570-003620	UNITED STATES	63/384,303	11/18/2022			5/16/2040	NON-AQUEOUS INTRANASAL DRUG COMPOSITIONS AND METHODS OF THEIR USE	Aegis Therapeutics, LLC	PENDING
148570-003920	UNITED STATES	63/384,305	11/18/2022			11/18/2023	PARENTERAL DRUG COMPOSITIONS AND METHODS OF THEIR USE	AEGIS THERAPEUTICS, LLC	PENDING
148570-004020	UNITED STATES	63/384,309	11/18/2022			11/18/2023	NON-AQUEOUS TOPICAL DRUG COMPOSITIONS AND METHODS OF USE	AEGIS THERAPEUTICS, LLC	PENDING
148570-004120	UNITED STATES	63/384,311	11/18/2022			11/18/2023	ORAL DRUG COMPOSITIONS AND METHODS OF USE	AEGIS THERAPEUTICS, LLC	PENDING
148570-004391OB	UNITED STATES	18/062,062	12/6/2022			3/27/2029	ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS	NEURELIS, INC.	Pending
148570-004401	UNITED STATES	18/125,940	3/24/2023			3/24/2043	INTRANASAL OLANZAPINE	NEURELIS, INC.	PENDING

								FORMULATIONS AND METHODS OF THEIR USE	
148570-004601 OB	UNITED STATES	17/837,198	6/10/2022		6/10/2042		METHODS AND COMPOSITIONS FOR TREATING SEIZURE DISORDERS IN PEDIATRIC PATIENTS	NEURELIS, INC.	Pending
148570-005900	UNITED STATES	63/350,936	6/10/2022		6/10/2023		POLYMORPHS OF SUBSTITUTED ISOQUINOLINE-BASED RHO KINASE INHIBITORS	BioAxxone BioSciences, Inc. NEURELIS, INC.	PENDING
148570-013401	UNITED STATES	18/149,366	1/3/2023		2/6/2038		COMPOSITIONS FOR DRUG ADMINISTRATION	Aegis Therapeutics, LLC L: ARS Pharmaceuticals, Inc.	PENDING

Item B. Patent Licenses.

None.